Stem Cell Therapy for Parkinson's in China: 2026 iPSC Trial Status, Eligibility and Access
- MedBridgeNZ
- Dec 18, 2025
- 18 min read
Updated: 6 days ago
By MedBridgeNZ | Last updated: 29 August 2026
For someone living with longer OFF periods—or for a family watching the benefits of medication become less predictable—the idea of replacing lost dopamine-producing neurons can feel both hopeful and urgent. It is also a difficult field to navigate. Headlines often use stem cell therapy for Parkinson's in China as if it were a single treatment, when the registered studies involve different cell products, protocols and hospitals.
China now has several programmes investigating induced pluripotent stem cell-derived dopaminergic cells. This guide explains what they are studying, how much evidence is available, what may be reviewed during trial screening and what an international patient should establish before considering travel.
Quick Answer
As of 29 August 2026, the Chinese Parkinson's iPSC programmes reviewed here remain clinical research pathways rather than routine treatment services. Each has its own product, protocol, eligibility criteria and recruitment position. International outpatient access at a hospital does not necessarily extend to its research studies.
Japan granted conditional and time-limited approval to the first iPSC-derived regenerative medicine for Parkinson's motor symptoms in March 2026. Regulatory decisions are country-specific, so patients looking at China still need to identify the relevant Chinese study and obtain a response from its hospital or research team before making travel plans.
Key Takeaways
iPSC-derived dopaminergic cell therapy is not the same as an unspecified "stem cell injection."
China has several distinct investigational programmes, using both patient-specific and donor-derived cell approaches.
Early clinical findings have moved the field forward, but small, open-label studies and single-patient reports cannot predict an individual's result.
Published criteria offer a first orientation; formal screening and enrolment remain decisions of the authorised study team.
International outpatient access, specialist consultation, trial pre-screening and formal trial enrolment are separate steps.
What Is iPSC Cell Therapy for Parkinson's Disease?
Parkinson's disease is associated with the progressive loss of dopaminergic neurons, particularly those projecting to the striatum. Medication can improve symptoms, and deep brain stimulation may help selected patients manage motor complications. Cell-replacement research starts from a different idea: could transplanted cells mature into dopamine-producing neurons and connect usefully with the brain's existing network?
The cells used in these programmes are not simply undifferentiated stem cells placed into the body. Researchers first reprogramme mature cells into induced pluripotent stem cells, or iPSCs, and then guide them towards a dopaminergic progenitor state. The resulting product is manufactured and tested under a defined protocol before stereotactic delivery, commonly into the putamen.
Follow-up focuses on whether the graft survives, matures and produces dopamine, as well as whether complications such as uncontrolled growth occur. Researchers also need to learn which Parkinson's symptoms may respond and which are unlikely to be changed by replacing dopaminergic cells.
iPSC Therapy Is Not a Catch-All Term for Stem Cell Treatment
Several very different approaches are described online as "stem cell therapy":
iPSC-derived dopaminergic cells are reprogrammed to pluripotency and then differentiated towards a dopaminergic lineage. The research goal is dopaminergic cell replacement through a controlled manufacturing and neurosurgical pathway.
Embryonic stem cell-derived dopaminergic cells pursue a similar replacement goal but begin with an embryonic stem cell line, so the donor source and manufacturing process are different.
Neural stem or progenitor cells are already committed towards neural lineages. Depending on the protocol, researchers may be studying neural repair, support or replacement.
Mesenchymal stromal cell approaches, often using cells from bone marrow, adipose tissue or perinatal sources, are generally investigated for trophic or immune-modulating effects. They should not be confused with a programme designed to replace dopamine-producing neurons.
The name of the product matters. A programme should be able to identify its cell source, manufacturing route, delivery method, study registration and responsible institution. Without those details, "stem cells for Parkinson's" tells a patient very little about what is actually being offered.
Autologous vs Allogeneic iPSC Therapy
When patients compare trial descriptions, one of the first unfamiliar terms they meet is whether the product is autologous or allogeneic. The difference is where the starting cells come from.
Autologous iPSC-Derived Cells
An autologous product begins with cells collected from the patient. Those cells are reprogrammed, differentiated and tested for use under that study's protocol. The patient-specific process may reduce some donor-compatibility concerns, although individualised manufacturing and quality control can take considerable time.
Allogeneic iPSC-Derived Cells
An allogeneic product uses a donor or cell-bank source. This can support more standardised manufacturing and, in some programmes, a prepared supply. The protocol may require immunosuppressive medication or another form of immune management.
For patients, the practical differences usually appear in preparation time, immune management and the manufacturing process—not in a simple judgment that one approach is automatically better. Whichever route is used, cell-line selection, purity, dose, surgery, quality testing and long-term monitoring all matter.
Is Parkinson's iPSC Therapy Approved in China or Elsewhere?
The short answer depends on the product and the country. Permission to run a clinical trial and approval to market a treatment are two different regulatory steps.
Japan's 2026 Conditional and Time-Limited Approval
On 6 March 2026, Sumitomo Pharma and RACTHERA announced that Japan had granted conditional and time-limited marketing authorisation to AMCHEPRY (raguneprocel), an allogeneic iPSC-derived dopaminergic neural progenitor cell product. Its stated indication covers improvement of motor symptoms in patients whose response to existing medicines, including levodopa-containing products, is inadequate. Post-marketing study and surveillance are required as part of the pathway towards full approval. (Sumitomo Pharma, 2026)
The decision drew on an investigator-initiated Phase I/II study at Kyoto University Hospital. Seven participants underwent safety assessment and six were included in efficacy analyses. At 24 months, the investigators reported no serious adverse events in the safety group, evidence of graft survival and dopamine production, and improvement in OFF-state motor scores in four of the six patients assessed for efficacy. The study was open-label, single-centre and small, leaving important questions for larger controlled trials. (Sawamoto et al., Nature, 2025)
For families following this field, Japan's decision is a meaningful milestone. Regulatory approvals are country-specific, however: it does not make AMCHEPRY approved in China, and it does not create automatic access for patients travelling from overseas.
The Current Position in China
China has multiple registered programmes investigating iPSC-derived dopaminergic cells. Some are investigator-initiated studies; others sit within a drug-development pathway after regulatory clearance to conduct a trial.
Terms such as investigational new drug (IND) clearance, trial registration and first participant dosed mark different stages of research. They tell us that a product may be studied, that a protocol has been made public or that treatment has begun under that protocol. Routine marketing approval is a later and separate decision.
Current Parkinson's iPSC Clinical Trials in China
Official trial registries are the best starting point for identifying a study, but they are not live appointment systems. The snapshot below shows the position recorded when this article was reviewed. Availability at a particular hospital—and access for someone living overseas—still needs to be checked directly.
Status last checked: 29 August 2026
Study and design | Cell approach and registered site | Registry position at review | What an international patient must still confirm |
UX-DA001, NCT06778265, Phase 1; estimated 12 participants | Autologous iPSC-derived midbrain dopaminergic progenitor cells; Shanghai UniXell Biotechnology and registered Ruijin sites | Active, not recruiting | Whether a later cohort or site is open and whether non-residents can be considered |
NCT06145711, small investigator-initiated study; target enrolment 3 | Autologous iPSC-derived dopaminergic neural precursor cells; Shanghai East Hospital with XellSmart collaboration | Recruiting in the last posted record; current site activity requires confirmation | Site access and follow-up requirements |
NouvNeu001, NCT06167681, Phase I/II; target enrolment 40 | Allogeneic iPSC-derived dopaminergic progenitor cells; iRegene Therapeutics and registered Chinese sites | ClinicalTrials.gov displayed the status as unknown | Whether a named site is actively enrolling and considers overseas participants |
NCT06821529, Phase 1; target enrolment 12 | Autologous iPSC-derived dopaminergic progenitor cells; iCamuno Biotherapeutics and a registered collaborator site | ClinicalTrials.gov displayed the status as unknown | Whether enrolment has opened, which site is active and how referrals are handled |
Active, not recruiting generally means that a study continues but is not accepting new participants. An unknown status does not prove that a study has closed; it means the record has not been recently verified to the registry's standard. In either situation, the named site is the right place to confirm what is currently happening.
Ruijin Hospital and UX-DA001
At Ruijin Hospital, UX-DA001 is being studied as an investigational autologous product. It is manufactured from a participant's own cells and implanted bilaterally into the putamen through stereotactic neurosurgery. The Phase 1 protocol focuses first on safety and tolerability while also exploring motor outcomes over two years. It lists an estimated 12 participants aged 50 to 75 and was marked active, not recruiting when this article was reviewed. (ClinicalTrials.gov: NCT06778265)
Public reports identify Professor Liu Jun of Ruijin Hospital's Department of Neurology as the principal investigator and Dr Li Dianyou of Functional Neurosurgery as the surgeon who performed the first transplantation. Trial leadership, neurological assessment, cell-product development and surgery are separate roles. (UniXell Biotech, 2025)
At the 2025 International Congress of Parkinson's Disease and Movement Disorders, the sponsor presented a six-month update on the first participant, including changes in motor scores, daily OFF time and imaging signals. A result from one person can support continued observation, but it cannot show how consistently other participants will respond. Full-cohort data and longer follow-up will be more informative. (UniXell Biotech, 2025)
To learn more about the hospital’s specialties, international services and overseas access process, see our Ruijin Hospital guide for international patients.
Other Chinese Programmes
NouvNeu001 follows a different route. It is an allogeneic iPSC-derived dopaminergic progenitor product in a registered Phase I/II programme. A 2024 conference abstract described early observations from the first participant alongside extensive preclinical findings. That is useful early scientific communication, although an abstract offers less detail than a complete peer-reviewed trial report. (MDS Abstracts, 2024)
There is no useful way to rank these programmes from headline milestones alone. They involve different products, sites, age ranges, disease-stage requirements and study designs. A criterion published for one trial may have no relevance to another.
If you are comparing programmes, our guide to verifying a Parkinson’s stem cell trial in China explains how to check the registry, sponsor, hospital site and current status before you travel.
What Does the Current Evidence Show About Parkinson's iPSC Therapy?
The clearest message is that the science has crossed an important threshold. Researchers have shown that pluripotent stem cell-derived dopaminergic progenitors can be transplanted into people, survive and produce dopamine over meaningful follow-up periods. The next question—whether this leads to dependable and lasting improvement for a wider group of patients—remains open.
The Kyoto Phase I/II trial is among the most informative peer-reviewed iPSC studies published so far. During 24 months of follow-up, investigators reported graft survival, dopamine production and no serious adverse events in the seven-patient safety cohort. Four of the six participants in the efficacy analysis improved on the OFF-state motor measure. The responses were not uniform, and the study had no control group. (Sawamoto et al., Nature, 2025)
Chinese programmes have so far been described through a mix of conference presentations, trial registries, hospital announcements and sponsor communications. Each type of source tells us something different:
A peer-reviewed clinical paper provides the most detail on methods, results and limitations.
A trial registry shows the planned protocol and recorded study status.
A conference abstract can share early findings before a full publication, usually with limited detail.
A sponsor or hospital announcement can confirm a milestone or present selected results, but it is not independent evidence.
Taken together, the evidence supports continued clinical research—not a claim of cure or predictable benefit. Larger controlled studies will need to show how often improvement occurs, how durable it is and how these approaches compare with established options such as optimised medication, infusion therapies or DBS. Results from selected participants with idiopathic Parkinson's disease also cannot be extended automatically to atypical, secondary or vascular parkinsonism.
Who May Be Considered for Parkinson's Cell-Therapy Trial Screening?
Age and disease duration are often the first details families check when reading a trial listing. They can offer a useful orientation, but they are only part of the screening picture.
Many dopamine cell-replacement trials focus on clinically established or idiopathic Parkinson's disease. Participants have often lived with the condition for several years, retain a measurable response to levodopa and are experiencing increasingly difficult symptom control. The thresholds vary from one protocol to another.
For example, UX-DA001 lists an age range of 50 to 75 and a Parkinson's history of 5 to 20 years. It also specifies a levodopa challenge response, an OFF-state Hoehn and Yahr stage of 3 to 4, stable medication and a reliable caregiver. Its exclusion criteria address atypical or secondary parkinsonism as well as genetic, infectious, malignant, neurological and systemic considerations. These are UX-DA001 requirements, not universal iPSC rules.
A study team may review several parts of the record:
how the diagnosis was made and whether the clinical course remains consistent with the protocol;
disease duration, progression and current motor and non-motor difficulties;
medication names, doses, timing, benefits, adverse effects and documented ON/OFF response;
available MDS-UPDRS or Hoehn and Yahr assessments;
previous DBS or other intracranial procedures;
cognitive, psychiatric, cardiovascular, cerebrovascular and systemic medical history;
MRI and other imaging already performed;
genetic or infection-screening results when required by the protocol;
ability to undergo stereotactic surgery and complete long-term follow-up; and
whether the patient and caregiver can comply with the study's visits and assessments.
In practice, a preliminary record review may reveal missing information or indicate that a formal screening conversation is worth pursuing. The final decision still belongs to the authorised research team working under the protocol.
For a closer look at the records and protocol factors commonly reviewed, read our guide to Parkinson’s stem cell trial eligibility in China.
Why Diagnostic Clarification May Come Before Trial Screening
Families often approach an overseas hospital with a particular treatment in mind. Being asked to revisit the diagnosis can feel like a detour, especially after years of appointments. For a movement-disorder specialist, however, it may be the most important place to start.
Parkinsonism describes a group of motor features that can include slowness, rigidity, tremor and impaired balance. Parkinson's disease is one cause, but atypical neurodegenerative disorders, vascular disease, medicines and other conditions can produce similar features. The distinction may affect both treatment planning and trial eligibility.
There is no single scan that settles every case. The Movement Disorder Society framework begins with the clinical diagnosis of parkinsonism and then considers exclusion criteria, red flags and supportive features. History and neurological examination remain central. (Postuma et al., 2015)
Dopamine-transporter imaging can add useful information in selected situations, but it has limits. Presynaptic dopaminergic imaging cannot reliably distinguish idiopathic Parkinson's disease from several other neurodegenerative parkinsonian syndromes, including progressive supranuclear palsy, corticobasal degeneration and the parkinsonian variant of multiple system atrophy. (EANM/SNMMI guideline)
Medication response is also part of the picture. Some cell-therapy protocols require documented improvement during a formal levodopa challenge. That is a trial-specific assessment rather than a test for patients to arrange or interpret on their own.
The aim of diagnostic clarification is not to add tests for the sake of it. It is to make sure that any next step addresses the right clinical question. A treating neurologist or receiving specialist should decide whether new imaging or testing would be useful.
Can International Patients Join Parkinson's Clinical Trials in China?
Potentially—but this is often the hardest question to answer from a public trial listing. A hospital's international medical centre may routinely see overseas private patients while a research programme in the same institution has separate rules, limited places or a demanding follow-up schedule.
It is more helpful to think of access as a series of steps than as one yes-or-no decision:
International outpatient access: the hospital can register and see an overseas patient.
Specialist consultation: a neurologist reviews the case and discusses appropriate next steps.
Trial pre-screening: the research team considers whether the available information broadly fits the protocol.
Formal screening: protocol-defined examinations, consent, imaging and laboratory checks are completed.
Enrolment: the authorised study team confirms participation.
An encouraging reply at an early stage may justify sending more information, but it is not yet an offer of enrolment.
Before travelling, ask the named site to confirm in writing whether it is actively enrolling and considers overseas residents. Also check whether records can be reviewed first, and clarify the language, caregiver, visit, follow-up and cost requirements.
Our guide to Parkinson’s clinical-trial access for international patients in China explains how outpatient consultation, pre-screening, formal screening and enrolment differ.
What Records May Be Needed for a Preliminary Review?
Preparing an overseas case file often takes longer than families expect. Reports may sit in different patient portals, medication lists may be out of date and imaging may exist only on a disc or viewer link. The goal is not to build a perfect archive. It is to give the receiving team a clear clinical story and access to the most relevant source records.
A practical first-review pack may include:
A concise clinical overview: when the diagnosis was made, how symptoms have changed, current concerns, major medical history and the purpose of the review.
A medication timeline: names, doses, timing, duration, benefits, adverse effects and reasons for stopping. Where known, note the difference between ON and OFF periods.
Neurological assessments: available MDS-UPDRS, Hoehn and Yahr or specialist examination records. Include movement videos only when requested and record them according to the receiving team's instructions.
Imaging already completed: written MRI, DaT-SPECT or PET reports, together with the original image files when requested.
Previous procedure records: DBS operative notes, device details and follow-up reports, along with relevant cardiovascular, cerebrovascular, cognitive, psychiatric or systemic history.
A short list of questions: for example, whether diagnostic clarification is needed, what established options remain and whether a particular research pathway is currently accessible.
Start with tests that have already been performed. There is no reason to arrange a new DaT scan, PET study or levodopa challenge simply because it appears in an online article. If another investigation is needed, the treating neurologist or receiving specialist can explain why.
If you are assembling a case file, our step-by-step guide to preparing medical records for a China specialist review explains how to organise reports, medication history, imaging and translations.
Imaging is a common source of delay. An online viewer may be convenient for the patient but may not let the receiving hospital download the complete study. If the team asks for the original MRI, the DICOM files are usually more useful than JPEGs, screen recordings or selected screenshots. Confirm the hospital's transfer method before uploading a large study.
For practical help with original scan files, see our DICOM imaging guide for China hospitals, including how to identify the correct files and confirm the receiving hospital’s transfer requirements.
Not sure whether your records are ready for specialist review?
MedBridgeNZ can help organise existing reports, medication history and imaging files, identify administrative gaps and coordinate an available review pathway before you make travel commitments.
How Much Does Parkinson's Stem Cell Therapy Cost in China?
Cost is often the next question after eligibility, but there is no reliable single price for Parkinson's cell therapy in China. The figure attached to an investigational product—if one is quoted—does not describe the full cost of screening, surgery, hospital care and long-term follow-up.
The sponsor or hospital should explain which protocol-related items are funded by the study and which remain patient-paid. For an overseas participant, travel, accommodation, translation and repeated visits can add substantial expenses that never appear in a trial listing.
Cost category | What should be confirmed in writing |
Investigational cell product | Whether it is supplied under the protocol and whether any charge applies |
Preliminary consultation and screening | Which consultations, imaging and laboratory tests are covered |
Surgery and hospitalisation | Whether theatre, anaesthesia, inpatient care and medicines are included |
Immune management | Whether immunosuppressive drugs and monitoring are required and covered |
Complication-related care | Responsibility under the consent, insurance and hospital arrangements |
Travel and accommodation | Flights, local transport, accommodation and caregiver costs |
Translation and coordination | Services separate from hospital or sponsor charges |
Long-term follow-up | Number, location and cost of required visits and tests |
If someone says that "the trial is free," ask exactly what that covers. The investigational product or certain protocol procedures may be funded while hospitalisation, travel, unrelated care or some follow-up expenses are not. Request a dated written fee scope before paying a deposit or booking non-refundable travel.
What Should You Verify Before Travelling to China?
A polished website or an encouraging email is not enough reason to organise international medical travel. Before treating a programme as a real option, confirm:
its registry number, official title and investigational product;
the cell source, sponsor and named hospital site;
whether that site is actively recruiting and considers overseas residents;
what records are needed before travel and who will review them;
how screening, consent, language support and caregiver requirements are handled;
how many in-person visits and how much long-term follow-up are expected;
which costs are study-funded and which are patient-paid; and
what document confirms movement from an enquiry to formal screening or enrolment.
Warning signs include a provider that cannot identify the protocol, promises a cure or guaranteed acceptance, requests a large treatment payment before study-team review, or discourages discussion with the patient's existing neurologist.
Until the authorised study team has completed its process, a consultation or preliminary discussion should be understood as exactly that—not confirmation of a trial place.
How MedBridgeNZ Supports the Pre-Travel Review Process
For most families, the useful first step is not booking a flight. It is finding out whether there is a credible pathway worth pursuing and whether the available records are sufficient for an initial review.
MedBridgeNZ can support that process by:
organising the available records into a structured case file;
coordinating medical translation without changing the clinical meaning of the source documents;
routing the case through an available specialist, hospital or authorised review pathway;
clarifying missing documents and communicating the receiving team's response; and
coordinating appointments, hospital logistics and travel if further assessment is offered.
This work sits on the administrative and cross-border coordination side of care. Diagnosis, new testing, trial eligibility, enrolment and treatment decisions remain with the receiving physicians, hospital and authorised study team.
Learn more about MedBridgeNZ’s medical concierge and cross-border coordination services, including record preparation, translation, hospital liaison and travel support.
Frequently Asked Questions
Is stem cell therapy for Parkinson's approved in China?
As of 29 August 2026, the Chinese programmes covered in this guide remain investigational. China has authorised or registered studies of several products, but permission to conduct research is not routine marketing approval.
Is iPSC therapy the same as a general stem cell injection?
No. The programmes discussed here manufacture dopaminergic progenitor cells from a defined iPSC source and deliver them to a protocol-specified brain target through stereotactic surgery. That is very different from an unspecified "stem cell injection."
Can international patients join Parkinson's clinical trials in China?
Possibly, but the answer varies by study and site. Residency, language, caregiver availability and the ability to complete long-term follow-up may all affect access for an overseas patient.
Who decides whether a patient is eligible?
The authorised investigators and study team decide through the trial's screening process. Published criteria can help someone understand the intended study population, but they cannot confirm an individual's eligibility.
Is iPSC cell therapy a cure for Parkinson's disease?
It is too early to describe iPSC cell therapy as a cure. Early studies have examined safety, graft survival, dopamine production and possible motor changes. Larger controlled trials and longer follow-up are needed to understand how consistent and durable any benefit may be.
Is the treatment free when it is part of a clinical trial?
Not necessarily. A sponsor may fund the investigational product or certain protocol procedures while consultations, hospital care, travel or other expenses remain patient-paid. Ask for the division of costs in writing.
Does previous DBS automatically rule someone out?
Not automatically. Different protocols treat prior procedures and implanted hardware differently. The trial team will need to review the operative history.
Do I need a DaT scan before requesting a review?
Not in every case. Send relevant imaging that has already been completed and let the treating neurologist or receiving specialist decide whether another test would help. Dopamine-transporter imaging cannot distinguish every form of neurodegenerative parkinsonism.
What MRI format should I submit?
Keep both the written radiology report and the original DICOM study where possible. A viewer link or JPEG may not meet a hospital's requirements, so confirm the transfer method before uploading large files.
Can a remote consultation confirm trial eligibility?
A remote review can identify missing records and show whether a formal screening discussion may be worthwhile. Protocol-defined examinations, consent and the final study-team decision usually still take place separately.
How long does an autologous iPSC pathway take?
There is no universal timeline. Cell collection, reprogramming, differentiation, manufacturing, quality testing and surgical scheduling can make an autologous pathway lengthy. The study team should provide the product-specific sequence.
Can MedBridgeNZ secure a place in a clinical trial?
No. MedBridgeNZ can prepare and translate records, coordinate an available review pathway and assist with logistics. Screening and enrolment are controlled by the authorised investigators and institution.
Making a Decision Before You Travel
Stem cell therapy for Parkinson's in China is no longer confined to laboratory research. Several clinical programmes are now studying the safety of iPSC-derived dopaminergic cell transplantation and whether it can produce meaningful functional change. That progress deserves attention, but the available human evidence is still early.
For a patient or family exploring this field, the next useful step is not choosing a treatment package from a headline. It is identifying the exact study, checking its current status and giving the responsible team enough information to say whether further review makes sense. Even when the answer is "not at this stage," establishing that before travel can save considerable time, expense and uncertainty.
Request a Parkinson's Case-Readiness Review
Considering a specialist review or an investigational Parkinson's programme in China? MedBridgeNZ can help organise your records, coordinate translation and route an enquiry through an available hospital or specialist review pathway before you make travel commitments. Any diagnosis, trial-eligibility assessment or treatment decision comes from the receiving medical team.
Ready to organise your enquiry? Request a MedBridgeNZ case-readiness review before making travel commitments.
References
Sumitomo Pharma and RACTHERA. Announcement on the Approval for Manufacturing and Marketing Authorization of AMCHEPRY in Japan. 6 March 2026. https://www.sumitomo-pharma.com/news/20260306.html
Sawamoto N, Doi D, Nakanishi E, et al. Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson's disease. Nature. 2025;641:971-977. https://www.nature.com/articles/s41586-025-08700-0
ClinicalTrials.gov. NCT06778265: An Exploratory Clinical Study of UX-DA001 in Subjects With Idiopathic Parkinson's Disease. Accessed 29 August 2026. https://clinicaltrials.gov/study/NCT06778265
ClinicalTrials.gov. NCT06145711: A Clinical Trial of Parkinson's Disease Treatment by hiPSC-Derived Dopaminergic Neural Precursor Cells. Accessed 29 August 2026. https://clinicaltrials.gov/study/NCT06145711
ClinicalTrials.gov. NCT06167681: The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease. Accessed 29 August 2026. https://clinicaltrials.gov/study/NCT06167681
ClinicalTrials.gov. NCT06821529: Stereotactic Intracerebral Injection of iPSC-DAPs in Patients With Parkinson's Disease. Accessed 29 August 2026. https://clinicaltrials.gov/study/NCT06821529
UniXell Biotechnology. Six-month case update for UX-DA001 presented at the 2025 International Congress of Parkinson's Disease and Movement Disorders. 13 October 2025.https://www.prnewswire.com/news-releases/unixell-biotech-reported-a-case-study-of-ux-da001-an-ipsc-derived-autologous-cell-therapy-for-parkinson-diseases-at-mds-congress-2025-302586177.html
Kayhanian S, Barker RA. Clinical trial highlights: dopamine cell-replacement therapies. Journal of Parkinson's Disease. Published online 25 November 2025. https://journals.sagepub.com/doi/10.1177/1877718X251397277
Cai M, Wei J, Ren X, et al. NouvNeu001, a Phase 1-stage chemically induced human dopaminergic progenitor cell therapy for mid- to late-stage Parkinson's disease. MDS Abstracts. 2024. https://www.mdsabstracts.org/abstract/nouvneu001-a-phase-1-stage-chemically-induced-human-dopaminergic-progenitor-cell-therapy-for-the-treatment-of-mid-to-late-stage-parkinsons-disease/
Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Movement Disorders. 2015;30(12):1591-1601. https://pubmed.ncbi.nlm.nih.gov/26474316/
Morbelli S, Esposito G, Arbizu J, et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes. European Journal of Nuclear Medicine and Molecular Imaging. 2020;47:1885-1912. https://pmc.ncbi.nlm.nih.gov/articles/PMC7300075/
Editorial notice: This article is intended for general educational and cross-border care-planning purposes. MedBridgeNZ Limited is a medical concierge and logistics coordination provider. It does not provide medical advice, diagnosis, treatment, clinical-trial eligibility decisions or investigational products. Trial status, hospital access and regulatory information may change after publication and should be confirmed with the responsible institution.
Author and editorial responsibility: MedBridgeNZ Limited. Source checking and editorial review cover documentation, logistics and cross-border coordination within MedBridgeNZ's non-clinical scope.
